Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Treatment strategies for neuroendocrine carcinoma of the upper digestive tract.

Morita M, Taguchi K, Kagawa M, Nakanoko T, Uehara H, Sugiyama M, Ota M, Ikebe M, Sugimachi K, Esaki T, Toh Y.

Int J Clin Oncol. 2020 Feb 8. doi: 10.1007/s10147-020-01631-y. [Epub ahead of print]

PMID:
32036480
2.

Lead Optimization and Avoidance of Reactive Metabolite Leading to PCO371, a Potent, Selective, and Orally Available Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist.

Nishimura Y, Esaki T, Isshiki Y, Furuta Y, Mizutani A, Kotake T, Emura T, Watanabe Y, Ohta M, Nakagawa T, Ogawa K, Arai S, Noda H, Kitamura H, Shimizu M, Tamura T, Sato H.

J Med Chem. 2020 Feb 17. doi: 10.1021/acs.jmedchem.9b01743. [Epub ahead of print]

PMID:
32022560
3.

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.

Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, Falcone A, Yamazaki K, Nishina T, Garcia-Carbonero R, Komatsu Y, Baba H, Argilés G, Tsuji A, Sobrero A, Yamaguchi K, Peeters M, Muro K, Zaniboni A, Sugimoto N, Shimada Y, Tsuji Y, Hochster HS, Moriwaki T, Tran B, Esaki T, Hamada C, Tanase T, Benedetti F, Makris L, Yamashita F, Lenz HJ.

Ann Oncol. 2020 Jan;31(1):88-95. doi: 10.1016/j.annonc.2019.10.005.

4.

Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.

Moriwaki T, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Hatachi Y, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Tsuji A, Tsuchihashi K, Sakai D, Ueno H, Tamura T, Yamashita K, Shimada Y.

Int J Clin Oncol. 2019 Dec 14. doi: 10.1007/s10147-019-01600-0. [Epub ahead of print]

PMID:
31838590
5.

Development of an in silico prediction system of human renal excretion and clearance from chemical structure information incorporating fraction unbound in plasma as a descriptor.

Watanabe R, Ohashi R, Esaki T, Kawashima H, Natsume-Kitatani Y, Nagao C, Mizuguchi K.

Sci Rep. 2019 Dec 11;9(1):18782. doi: 10.1038/s41598-019-55325-1.

6.

Novel anti-flavivirus drugs targeting the nucleolar distribution of core protein.

Tokunaga M, Miyamoto Y, Suzuki T, Otani M, Inuki S, Esaki T, Nagao C, Mizuguchi K, Ohno H, Yoneda Y, Okamoto T, Oka M, Matsuura Y.

Virology. 2020 Feb;541:41-51. doi: 10.1016/j.virol.2019.11.015. Epub 2019 Nov 29.

PMID:
31826845
7.

Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer.

Masuishi T, Taniguchi H, Kotani D, Bando H, Komatsu Y, Shinozaki E, Nakajima TE, Satoh T, Nishina T, Esaki T, Wakabayashi M, Nomura S, Takahashi K, Ono H, Hirano N, Fujishiro N, Fuse N, Sato A, Ohtsu A, Yoshino T.

ESMO Open. 2019 Nov 13;4(6):e000590. doi: 10.1136/esmoopen-2019-000590. eCollection 2019.

8.

Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.

Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M.

Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25.

PMID:
31768696
9.

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.

Hamaguchi T, Denda T, Kudo T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Chiron M, Yoshino T.

Cancer Sci. 2019 Nov;110(11):3565-3572. doi: 10.1111/cas.14198. Epub 2019 Oct 21.

10.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.

Shitara K, Satoh T, Iwasa S, Yamaguchi K, Muro K, Komatsu Y, Nishina T, Esaki T, Hasegawa J, Kakurai Y, Kamiyama E, Nakata T, Nakamura K, Sakaki H, Hyodo I.

J Immunother Cancer. 2019 Aug 14;7(1):219. doi: 10.1186/s40425-019-0679-9.

11.

Constructing an In Silico Three-Class Predictor of Human Intestinal Absorption With Caco-2 Permeability and Dried-DMSO Solubility.

Esaki T, Ohashi R, Watanabe R, Natsume-Kitatani Y, Kawashima H, Nagao C, Komura H, Mizuguchi K.

J Pharm Sci. 2019 Nov;108(11):3630-3639. doi: 10.1016/j.xphs.2019.07.014. Epub 2019 Jul 25.

PMID:
31351866
12.

Computational Model To Predict the Fraction of Unbound Drug in the Brain.

Esaki T, Ohashi R, Watanabe R, Natsume-Kitatani Y, Kawashima H, Nagao C, Mizuguchi K.

J Chem Inf Model. 2019 Jul 22;59(7):3251-3261. doi: 10.1021/acs.jcim.9b00180. Epub 2019 Jul 11.

PMID:
31260629
13.

Development of Simplified in Vitro P-Glycoprotein Substrate Assay and in Silico Prediction Models To Evaluate Transport Potential of P-Glycoprotein.

Ohashi R, Watanabe R, Esaki T, Taniguchi T, Torimoto-Katori N, Watanabe T, Ogasawara Y, Takahashi T, Tsukimoto M, Mizuguchi K.

Mol Pharm. 2019 May 6;16(5):1851-1863. doi: 10.1021/acs.molpharmaceut.8b01143. Epub 2019 Apr 16.

14.

Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients.

Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, Komoda M, Kono M, Fukata M, Arita T, Esaki T, Akashi K, Baba E.

Gastric Cancer. 2019 Sep;22(5):988-998. doi: 10.1007/s10120-019-00930-2. Epub 2019 Feb 20.

PMID:
30788749
15.

Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.

Esaki T, Hirai F, Makiyama A, Seto T, Bando H, Naito Y, Yoh K, Ishihara K, Kakizume T, Natsume K, Myers A, Doi T.

Cancer Sci. 2019 Apr;110(4):1340-1351. doi: 10.1111/cas.13956. Epub 2019 Feb 20.

16.

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.

Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T.

Cancer Sci. 2019 Mar;110(3):1032-1043. doi: 10.1111/cas.13943. Epub 2019 Feb 22.

17.

Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.

Yoshihiro T, Kusaba H, Makiyama A, Kobayashi K, Uenomachi M, Ito M, Doi Y, Mitsugi K, Aikawa T, Takayoshi K, Esaki T, Shimokawa H, Tsuchihashi K, Ariyama H, Akashi K, Baba E.

Int J Clin Oncol. 2019 May;24(5):508-515. doi: 10.1007/s10147-018-01391-w. Epub 2019 Jan 2.

PMID:
30604155
18.

A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).

Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsuji A, Fujii H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N.

Gastric Cancer. 2019 Mar;22(2):344-354. doi: 10.1007/s10120-018-0899-6. Epub 2018 Dec 1.

19.

Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.

Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, Nishina T, Hara H, Machida N, Komatsu Y, Shimada Y, Otsu S, Shimizu S, Watanabe M.

Gastric Cancer. 2019 Jul;22(4):817-827. doi: 10.1007/s10120-018-0903-1. Epub 2018 Dec 4.

20.

A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients.

Hamaguchi T, Tsuji A, Yamaguchi K, Takeda K, Uetake H, Esaki T, Amagai K, Sakai D, Baba H, Kimura M, Matsumura Y, Tsukamoto T.

Cancer Chemother Pharmacol. 2018 Dec;82(6):1021-1029. doi: 10.1007/s00280-018-3693-6. Epub 2018 Oct 4.

21.

Predicting Fraction Unbound in Human Plasma from Chemical Structure: Improved Accuracy in the Low Value Ranges.

Watanabe R, Esaki T, Kawashima H, Natsume-Kitatani Y, Nagao C, Ohashi R, Mizuguchi K.

Mol Pharm. 2018 Nov 5;15(11):5302-5311. doi: 10.1021/acs.molpharmaceut.8b00785. Epub 2018 Sep 27.

PMID:
30259749
22.

Data Curation can Improve the Prediction Accuracy of Metabolic Intrinsic Clearance.

Esaki T, Watanabe R, Kawashima H, Ohashi R, Natsume-Kitatani Y, Nagao C, Mizuguchi K.

Mol Inform. 2019 Jan;38(1-2):e1800086. doi: 10.1002/minf.201800086. Epub 2018 Sep 24.

23.

Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.

Yoshino T, Yamazaki K, Shinozaki E, Komatsu Y, Nishina T, Baba H, Tsuji A, Tsuji Y, Yamaguchi K, Sugimoto N, Denda T, Muro K, Takayama T, Esaki T, Hamamoto Y, Moriwaki T, Shimada Y, Goto M, Nakayama N, Fujii H, Tanase T, Ohtsu A.

Clin Colorectal Cancer. 2018 Dec;17(4):e719-e732. doi: 10.1016/j.clcc.2018.07.009. Epub 2018 Jul 26.

24.

Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.

Tsuchihashi K, Ito M, Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama A, Denda T, Satake H, Suto T, Sugimoto N, Katsumata K, Ishikawa T, Kashiwada T, Oki E, Komatsu Y, Okuyama H, Sakai D, Ueno H, Tamura T, Yamashita K, Kishimoto J, Shimada Y, Baba E.

Clin Colorectal Cancer. 2018 Dec;17(4):e687-e697. doi: 10.1016/j.clcc.2018.07.004. Epub 2018 Jul 29.

PMID:
30149986
25.

Epithelial-mesenchymal transition is activated in CD44-positive malignant ascites tumor cells of gastrointestinal cancer.

Nakano M, Ito M, Tanaka R, Ariyama H, Mitsugi K, Makiyama A, Uchino K, Esaki T, Tsuruta N, Hanamura F, Yamaguchi K, Okumura Y, Sagara K, Takayoshi K, Nio K, Tsuchihashi K, Tamura S, Shimokawa H, Arita S, Miyawaki K, Kusaba H, Akashi K, Baba E.

Cancer Sci. 2018 Nov;109(11):3461-3470. doi: 10.1111/cas.13777. Epub 2018 Sep 27.

26.

The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer.

Yamaguchi K, Kusaba H, Makiyama A, Mitsugi K, Uchino K, Tamura S, Shibata Y, Esaki T, Ito M, Takayoshi K, Tsuchihashi K, Arita S, Ariyama H, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2018 Oct;82(4):625-633. doi: 10.1007/s00280-018-3652-2. Epub 2018 Jul 24.

PMID:
30043209
27.

Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism.

Nishimura Y, Esaki T, Isshiki Y, Okamoto N, Furuta Y, Kotake T, Watanabe Y, Ohta M, Nakagawa T, Noda H, Shimizu M, Saito H, Tamura T, Sato H.

J Med Chem. 2018 Jul 26;61(14):5949-5962. doi: 10.1021/acs.jmedchem.8b00182. Epub 2018 Jul 3.

PMID:
29932656
28.

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.

Kumagai H, Kusaba H, Yamanaka T, Nio K, Inadomi K, Takayoshi K, Ito M, Tamura S, Makiyama A, Makiyama C, Hirano G, Shibata Y, Shirakawa T, Mitsugi K, Ariyama H, Esaki T, Akashi K, Baba E.

Medicine (Baltimore). 2018 Jun;97(25):e11042. doi: 10.1097/MD.0000000000011042.

29.

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.

Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W.

Gastric Cancer. 2019 Jan;22(1):155-163. doi: 10.1007/s10120-018-0838-6. Epub 2018 May 31.

30.

Systemic Lupus Erythematosus and Sjögren's Syndrome Complicated by Conversion Disorder: a Case Report.

Nakamura M, Tanaka S, Inoue T, Maeda Y, Okumiya K, Esaki T, Shimomura GO, Masunaga K, Nagamitsu S, Yamashita Y.

Kurume Med J. 2018 Jul 10;64(4):97-101. doi: 10.2739/kurumemedj.MS644005. Epub 2018 May 21.

31.

pH after the first session of direct hemoperfusion with polymyxin B-immobilized fibers predicts mortality in patients with sepsis and septic shock.

Okubo A, Nakashima A, Doi S, Ueno T, Sasaki K, Esaki T, Masaki T.

Clin Exp Nephrol. 2018 Oct;22(5):1167-1173. doi: 10.1007/s10157-018-1548-4. Epub 2018 Feb 24.

PMID:
29478200
32.

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.

Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1.

PMID:
29397354
33.

First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.

Makiyama A, Kunieda K, Noguchi M, Kajiwara T, Tamura T, Takeda K, Sugiyama J, Minashi K, Moriwaki T, Sugimoto N, Nagase M, Negoro Y, Tsuda T, Shimodaira H, Okano N, Tsuji A, Sakai D, Yanagihara K, Ueda S, Tamura S, Otsu S, Honda T, Matsushita Y, Okuno T, Kashiwada T, Nozaki A, Ebi M, Okuda H, Shimokawa M, Hironaka S, Hyodo I, Baba E, Boku N, Muro K, Esaki T.

Gastric Cancer. 2018 Sep;21(5):792-801. doi: 10.1007/s10120-018-0797-y. Epub 2018 Jan 20.

PMID:
29353332
34.

Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM.

Am J Hematol. 2018 May;93(5):607-614. doi: 10.1002/ajh.25043. Epub 2018 Feb 8.

35.

Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.

Kajitani T, Makiyama A, Arita S, Shimokawa H, Oda H, Shirakawa T, Baba E, Esaki T.

Anticancer Res. 2017 Nov;37(11):6459-6468.

PMID:
29061833
36.

Dual Roles of Glutathione in Ecdysone Biosynthesis and Antioxidant Function During Larval Development in Drosophila.

Enya S, Yamamoto C, Mizuno H, Esaki T, Lin HK, Iga M, Morohashi K, Hirano Y, Kataoka H, Masujima T, Shimada-Niwa Y, Niwa R.

Genetics. 2017 Dec;207(4):1519-1532. doi: 10.1534/genetics.117.300391. Epub 2017 Oct 11.

37.

Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.

Ito M, Kusaba H, Mukaide S, Kishimoto J, Shimokawa H, Tamura S, Makiyama A, Hirano G, Oda H, Shirakawa T, Komoda M, Uchino K, Tanaka R, Mitsugi K, Esaki T, Arita S, Ariyama H, Akashi K, Baba E.

Anticancer Drugs. 2017 Nov;28(10):1166-1173. doi: 10.1097/CAD.0000000000000562.

PMID:
28906258
38.

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.

Moriwaki T, Fukuoka S, Taniguchi H, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Esaki T, Makiyama C, Denda T, Satake H, Suto T, Sugimoto N, Enomoto M, Ishikawa T, Kashiwada T, Sugiyama M, Komatsu Y, Okuyama H, Baba E, Sakai D, Watanabe T, Tamura T, Yamashita K, Gosho M, Shimada Y.

Oncologist. 2018 Jan;23(1):7-15. doi: 10.1634/theoncologist.2017-0275. Epub 2017 Sep 11.

39.

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.

Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E.

Gastric Cancer. 2018 May;21(3):464-472. doi: 10.1007/s10120-017-0759-9. Epub 2017 Aug 10.

PMID:
28799048
40.

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.

Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2017 Aug;80(2):333-342. doi: 10.1007/s00280-017-3371-0. Epub 2017 Jun 26.

PMID:
28653251
41.

Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer.

Inadomi K, Kusaba H, Matsushita Y, Tanaka R, Mitsugi K, Arimizu K, Hirano G, Makiyama A, Ohmura H, Uchino K, Hanamura F, Shibata Y, Kuwayama M, Esaki T, Takayoshi K, Arita S, Ariyama H, Akashi K, Baba E.

Anticancer Res. 2017 May;37(5):2663-2671.

PMID:
28476842
42.

LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer.

Takahashi S, Kobayashi T, Tomomatsu J, Ito Y, Oda H, Kajitani T, Kakizume T, Tajima T, Takeuchi H, Maacke H, Esaki T.

Cancer Chemother Pharmacol. 2017 Jan;79(1):131-138. doi: 10.1007/s00280-016-3214-4. Epub 2016 Dec 9.

43.

Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report.

Hanamura F, Shibata Y, Shirakawa T, Kuwayama M, Oda H, Ariyama H, Taguchi K, Esaki T, Baba E.

Mol Clin Oncol. 2016 Nov;5(5):579-582. Epub 2016 Sep 21.

44.

Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.

Tamura T, Noda H, Joyashiki E, Hoshino M, Watanabe T, Kinosaki M, Nishimura Y, Esaki T, Ogawa K, Miyake T, Arai S, Shimizu M, Kitamura H, Sato H, Kawabe Y.

Nat Commun. 2016 Nov 18;7:13384. doi: 10.1038/ncomms13384.

45.

Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.

Kuba S, Ishida M, Oikawa M, Nakamura Y, Yamanouchi K, Tokunaga E, Taguchi K, Esaki T, Eguchi S, Ohno S.

Breast Cancer. 2016 Nov;23(6):945-949. Epub 2016 Feb 15. Review.

PMID:
26879549
46.

Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors.

Mukai H, Kato K, Esaki T, Ohsumi S, Hozomi Y, Matsubara N, Hamaguchi T, Matsumura Y, Goda R, Hirai T, Nambu Y.

Invest New Drugs. 2016 Dec;34(6):750-759. Epub 2016 Sep 5.

47.

Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.

Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y.

Cancer Chemother Pharmacol. 2016 Sep;78(3):525-31. doi: 10.1007/s00280-016-3106-7. Epub 2016 Jul 15.

48.

Direct evidence of specific localization of sesquiterpenes and marchantin A in oil body cells of Marchantia polymorpha L.

Tanaka M, Esaki T, Kenmoku H, Koeduka T, Kiyoyama Y, Masujima T, Asakawa Y, Matsui K.

Phytochemistry. 2016 Oct;130:77-84. doi: 10.1016/j.phytochem.2016.06.008. Epub 2016 Jul 9.

PMID:
27406893
49.

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).

Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I.

Ann Oncol. 2016 Aug;27(8):1539-46. doi: 10.1093/annonc/mdw206. Epub 2016 May 13.

50.

Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).

Tsuburaya A, Sugimoto N, Imamura H, Nishikawa K, Imamoto H, Tsujinaka T, Esaki T, Horita Y, Kimura Y, Fujiya T, Takayama O, Oono R, Yabusaki H, Taguri M, Morita S, Yamada Y, Tan P, Ninomiya M, Furukawa H, Sasako M.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e45-51. doi: 10.1016/j.clon.2016.04.001. Epub 2016 Apr 30.

PMID:
27142170

Supplemental Content

Support Center